Journals / The Journal of Pediatric Research / 2021 / Cilt: 8 - Sayı: 3

The Evaluation of Skeletal Manifestations in Patients with Gaucher Disease

Pages
257–261
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is a need to enhance awareness and to improve the diagnosis and treatment of skeletal pathology in patients with GD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Gaucher disease (GD) is the most prevalent hereditary lysosomal storage disorder, affecting multiple organ systems.
📊
Key Findings & Data:This article gives an overview of the bone manifestations of 20 GD patients and reviews the current literature.
💡
Conclusion & Impact:There is a need to enhance awareness and to improve the diagnosis and treatment of skeletal pathology in patients with GD.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: Gaucher disease (GD) is the most prevalent hereditary lysosomal storage disorder, affecting multiple organ systems. It is characterized by a deficiency of the enzyme glucocerebrosidase leading to an accumulation of glucosylceramide in lysosomes. The majority of patients present with hepatosplenomegaly, anemia, thrombocytopenia, bleeding tendencies, skeletal pathologies, growth retardation and in severe cases pulmonary disease. The bone manifestations include bone infarcts, avascular bone necrosis, lytic lesions, osteopenia and osteoporosis. This article gives an overview of the bone manifestations of 20 GD patients and reviews the current literature. Materials and Methods: The data of 20 patients with GD who were being followed up in Gazi University Hospital Pediatric Metabolism Unit were retrospectively evaluated. Their demographic information including age, gender, clinical findings, enzyme replacement therapy (ERT) status and duration were recorded. Laboratory analyses including serum calcium, phosphorus, vitamin D, the presence of skeletal findings, and bone mineral density (BMD) Z scores were collected from the patient files. The BMD status of patients was compared with their pre-treatment values. Results: The main symptoms of referral were abdominal distention, cytopenia, bleeding tendency and skeletal findings. All patients had skeletal symptoms. Nineteen patients showed vitamin D deficiency. The medullary involvement of femur and vertebrae was present in 14 (70%), Erlenmeyer flask deformity in 3 (15%), and avascular necrosis in one (5%) patient. Also, one patient (5%) had lytic bone lesions. Ten patients showed osteoporosis (50%), and 8 showed osteopenia (40%) at the time of diagnosis, before the initiation of ERT. The rate of osteoporosis was determined to be 40%, and osteopenia was 35% within the study group after the initiation of ERT. Conclusion: Physicians, including pediatricians, may be unfamiliar with bone pathophysiology and the complexity of the skeletal manifestations of GD. There is a need to enhance awareness and to improve the diagnosis and treatment of skeletal pathology in patients with GD.

🔖

Cite This Article

KASAPKARA, Ç. S., KILIÇKAYA, M., OKUR, İ., EZGÜ, F. S., TÜMER, L. (2021). The Evaluation of Skeletal Manifestations in Patients with Gaucher Disease. The Journal of Pediatric Research, Cilt: 8 - Sayı: 3, 257–261. https://ajindex.com/articles/362862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mikosch P. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone. Best Pract Res Clin Rheumatol 2011; 25:665-81
  2. Hughes D, Mikosch P, Belmatoug N, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res 2019; 34:996-1013
  3. Braegger C, Campoy C, Colomb V, et al; Vitamin D in the healthy European pediatric population. ESPGHAN Commitee on Nutrition. J Pediatr Gastroenterol Nutr 2013; 56:692-701
  4. Lewiecki EM, Gordon CM, Baim S, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone 2008; 43:1115-21
  5. Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 2010; 160:609-24
  6. Rossi L, Zulian F, Stirnemann J, Billette de Villemur T, Belmatoug N. Bone involvement as presenting sign of pediatric-onset Gaucher disease. Joint Bone Spine 2011; 78:70-4
  7. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002; 75(Suppl 1):A2-12. doi: 10.1259/bjr.75.suppl_1.750002
  8. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996; 11:1801- 7
  9. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835-43
  10. Mistry PK, Weinreb NJ, Kaplan P, et al. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011; 46:66-72
  11. De Fost M, Hollak CEM, Groener JEM, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2- center retrospective analysis. Blood 2006; 108:830-5
  12. Robertson PL, Maas M, Goldblatt J. Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher’s disease using the bone marrow burden score. AJR Am J Roentgenol 2007; 188:1521-8
  13. Maas M, van Kujik C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience. Radiology 2003; 229:554-61
  14. Lukina E, Watman N, Dragosky M, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the Phase 2 trial. Am J Hematol 2019; 94:29-38